MoonLake Immunotherapeutics Statistics
Share Statistics
MoonLake Immunotherapeutics has 63.06M shares outstanding. The number of shares has increased by 4.92% in one year.
| Shares Outstanding | 63.06M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.02% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 52.84M |
| Failed to Deliver (FTD) Shares | 19 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 8.06M, so 12.79% of the outstanding shares have been sold short.
| Short Interest | 8.06M |
| Short % of Shares Out | 12.79% |
| Short % of Float | 15.27% |
| Short Ratio (days to cover) | 21.44 |
Valuation Ratios
The PE ratio is -82.39 and the forward PE ratio is -20.67.
| PE Ratio | -82.39 |
| Forward PE | -20.67 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 5.98 |
| P/FCF Ratio | -68.89 |
| PEG Ratio | n/a |
Enterprise Valuation
MoonLake Immunotherapeutics has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 51.59, with a Debt / Equity ratio of 0.
| Current Ratio | 51.59 |
| Quick Ratio | 51.59 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.07% and return on capital (ROIC) is -10.49%.
| Return on Equity (ROE) | -0.07% |
| Return on Assets (ROA) | -0.07% |
| Return on Capital (ROIC) | -10.49% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -720.15K |
| Employee Count | 50 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 94.39K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -15.27% in the last 52 weeks. The beta is 1.28, so MoonLake Immunotherapeutics's price volatility has been higher than the market average.
| Beta | 1.28 |
| 52-Week Price Change | -15.27% |
| 50-Day Moving Average | 50.52 |
| 200-Day Moving Average | 46.57 |
| Relative Strength Index (RSI) | 55.07 |
| Average Volume (20 Days) | 294.60K |
Income Statement
In the last 12 months, MoonLake Immunotherapeutics had revenue of $0 and earned -$36.01M in profits. Earnings per share was $-0.73.
| Revenue | 0 |
| Gross Profit | -13.16K |
| Operating Income | -54.12M |
| Net Income | -36.01M |
| EBITDA | -54.11M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.73 |
Balance Sheet
The company has $451.17M in cash and $3.81M in debt, giving a net cash position of $447.36M.
| Cash & Cash Equivalents | 451.17M |
| Total Debt | 3.81M |
| Net Cash | 447.36M |
| Retained Earnings | -116.66M |
| Total Assets | 518.21M |
| Working Capital | 492.24M |
Cash Flow
In the last 12 months, operating cash flow was -$42.78M and capital expenditures -$284.63K, giving a free cash flow of -$43.06M.
| Operating Cash Flow | -42.78M |
| Capital Expenditures | -284.63K |
| Free Cash Flow | -43.06M |
| FCF Per Share | -0.88 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
MLTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1.42% |
| FCF Yield | -1.33% |
Analyst Forecast
The average price target for MLTX is $71, which is 38.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $71 |
| Price Target Difference | 38.2% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | 90 |
| Piotroski F-Score | 2 |